ClinicalTrials.gg
CompletedNCT02201004Updated Oct 11, 2017

TOFO Insulin Combination Trial

A Phase 4 interventional study of TOFOGLIFLOZIN CSG452 and insulin in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 30 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-11.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
12th of 54
211 · median 60
Started
2014
with 2 others
Phase 4
20 of 54
2 open now
Registered
35th of 54
by date

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 20 in phase 4, and was the 35th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objectives:

To assess the effects of tofogliflozin on glycemic control in comparison to placebo as an add-on treatment to insulin treatment in terms of glycated hemoglobin (HbA1c) reduction over a period of 16 weeks in patients with type 2 diabetes mellitus.

To assess the safety of tofogliflozin in combination with insulin treatment throughout 52 weeks.

Secondary Objectives:

To assess the effects of tofogliflozin in comparison to placebo on:

  • Body weight
  • Fasting plasma glucose (FPG)
  • Postprandial plasma glucose (PPG) To assess the long term safety and tolerability of tofogliflozin.
Read the detailed description

The total study duration from screening for a patient can be approximately up to 1 year, including a screening period of 2 weeks, double-blinded placebo controlled treatment period of 16 weeks, an open-labeled extension period of 36 weeks, and a follow-up period of 3 days.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 20-75 years old with type 2 diabetes mellitus (T2DM).
  • ≥7.5% - ≤10.5% and FPG ≤220 mg/dL.
  • Basal bolus (BB), Bolus, Premix, Basal supported oral therapy (BOT) regimens used for more than 12 weeks before screening.
  • Stable dose (-/+20%) of insulin and no change in the dose of oral hypoglycemic agents for more than 12 weeks before screening.
  • Only Dipeptidyl peptidase-4 inhibitor is allowed for basal supported oral therapy (BOT) regimen.
  • (BMI) ≥18.5 kg/m\^2 and \<35.0 kg/m\^2.
  • No change of antihypertensive, anti-hypercholesterolemia and uric acid lowering drug 4 weeks before screening.

Exclusion criteria

Exclusion criteria:

  • Type 1 diabetes mellitus.
  • Pregnancy or lactation.
  • Severely uncontrolled glycemic situation.
  • History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening.
  • History of myocardial infarction, stroke, or heart failure requiring hospitalization or drug or alcohol abuse within the previous 6 months.
  • A measured serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL for women.
  • (AST) or alanine aminotransferase (ALT) ≥2.5 times the upper limit of the reference range at the central laboratory test facility.
  • Has previously received treatment with the product.
  • Has received treatment with another investigational product or non-approved drug within 3 months before tests for provisional enrolment.
  • therapy for 14 or more days in total within 8 weeks before tests for provisional enrolment (excluding those used for localized effects, such as drugs for topical [skin] application, eye drops and sprays).
  • Patients who are frequently experiencing orthostatic hypotension.
  • Required a change in the dosing regimen for the following drugs within 4 weeks before tests for provisional enrolment:
  • Lipid-lowering drug
  • Antihypertensive drug
  • Thyroid hormone preparation
  • Uric acid lowering drug

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    tofogliflozin

    Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.

    Drug: TOFOGLIFLOZIN CSG452 · Drug: insulin

  • Placebo comparator
    placebo

    Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.

    Drug: TOFOGLIFLOZIN CSG452 · Drug: insulin · Drug: placebo

Interventions

  • Pharmaceutical form:tablet Route of administration: oral

    Also known as: Apleway, Deberza

  • Pharmaceutical form:solution Route of administration: subcutaneous

  • Drugplacebo

    Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline

    Time frame: 16 weeks after first intake of investigational product

Secondary outcomes

  1. Change of Body Weight (BW) from baseline

    Time frame: 16 weeks after first intake of investigational product

  2. Change of FPG from baseline

    Time frame: 16 weeks after first intake of investigational product

  3. Change of PPG from baseline

    Time frame: 16 weeks after first intake of investigational product

  4. Number of subjects with adverse events

    Time frame: Up to 52 weeks from the first intake of investigational medicinal product

07

Study locations

30 sites
  • Investigational Site Number 392-028
    Adachi-ku, Japan
  • Investigational Site Number 392-007
    Atsugi-shi, Japan
  • Investigational Site Number 392-026
    Chuoh-ku, Japan
  • Investigational Site Number 392-021
    Fukuoka-shi, Japan
  • Investigational Site Number 392-002
    Ichihara-shi, Japan
  • Investigational Site Number 392-012
    Iruma-shi, Japan
  • Investigational Site Number 392-003
    Kawaguchi-shi, Japan
  • Investigational Site Number 392-014
    Kitakyusyu-shi, Japan
  • Investigational Site Number 392-027
    Kobe-shi, Japan
  • Investigational Site Number 392-004
    Koga-shi, Japan
  • Investigational Site Number 392-022
    Kunitachi-shi, Japan
  • Investigational Site Number 392-019
    Kurume-shi, Japan
  • Investigational Site Number 392-001
    Kyoto-shi, Japan
  • Investigational Site Number 392-024
    Kyoto-shi, Japan
  • Investigational Site Number 392-006
    Matsudo-shi, Japan
  • Investigational Site Number 392-008
    Mito-shi, Japan
  • Investigational Site Number 392-030
    Musashino-shi, Japan
  • Investigational Site Number 392-029
    Okayama-shi, Japan
  • Investigational Site Number 392-017
    Otsu-shi, Japan
  • Investigational Site Number 392-011
    Sagamihara-shi, Japan
  • Investigational Site Number 392-020
    Sakai-shi, Japan
  • Investigational Site Number 392-010
    Sapporo-shi, Japan
  • Investigational Site Number 392-016
    Sendai-shi, Japan
  • Investigational Site Number 392-018
    Shinjuku-ku, Japan
  • Investigational Site Number 392-005
    Shizuoka-shi, Japan
  • Investigational Site Number 392-031
    Suita-shi, Japan
  • Investigational Site Number 392-015
    Sumida-ku, Japan
  • Investigational Site Number 392-023
    Sunto-gun, Japan
  • Investigational Site Number 392-013
    Tokorozawa-shi, Japan
  • Investigational Site Number 392-025
    Yokohama-shi, Japan
08

References and documents

Publications

  • Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017 Oct;19(10):1397-1407. doi: 10.1111/dom.12957. Epub 2017 Jul 13. PubMed 28371205 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jan 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2014
First posted
Jul 25, 2014
Start
Jun 2014
Primary completionActual
Jan 2016
CompletionActual
Oct 2016
Last update
Oct 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02201004
Lead sponsor
Sanofi
Collaborators
Kowa Company, Ltd.
Responsible party
Sponsor
First posted
Jul 25, 2014
Start date
Jun 2014
Primary completion
Jan 2016
Completion
Oct 2016
Last update
Oct 11, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion